Compare CNXN & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNXN | IMNM |
|---|---|---|
| Founded | 1982 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | 1998 | 2020 |
| Metric | CNXN | IMNM |
|---|---|---|
| Price | $61.21 | $20.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $31.44 |
| AVG Volume (30 Days) | 82.3K | ★ 1.8M |
| Earning Date | 02-04-2026 | 11-06-2025 |
| Dividend Yield | ★ 0.98% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.24 | N/A |
| Revenue | ★ $2,878,704,000.00 | $9,679,000.00 |
| Revenue This Year | $5.85 | N/A |
| Revenue Next Year | $4.52 | N/A |
| P/E Ratio | $18.82 | ★ N/A |
| Revenue Growth | ★ 3.19 | N/A |
| 52 Week Low | $54.97 | $5.15 |
| 52 Week High | $75.08 | $25.30 |
| Indicator | CNXN | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 59.51 | 54.16 |
| Support Level | $58.95 | $18.81 |
| Resistance Level | $61.45 | $25.30 |
| Average True Range (ATR) | 1.25 | 1.56 |
| MACD | 0.37 | 0.13 |
| Stochastic Oscillator | 85.37 | 37.75 |
PC Connection Inc is a provider of information technology solutions. It provides products such as computer systems, software and peripheral equipment, networking communications, and other products and accessories that company purchase from manufacturers and distributors. The company also offers services involving design, configuration, and implementation of IT solutions. It conducts business operations through three business segments namely Connection Business Solutions, Connection Enterprise Solutions, and Connection Public Sector Solutions. The company generates maximum revenue Connection Enterprise Solutions segment.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.